RAS and Rho small GTPases are key molecular switches that control cell dynamics, cell growth and tissue development through their distinct signaling pathways. Although much has been learnt about their individual functions in both cell and animal models, the physiological and pathophysiological consequences of their signaling crosstalk in multi-cellular context in vivo remain largely unknown, especially in liver development and liver tumorigenesis. Furthermore, the roles of RhoA in RAS-mediated transformation and their crosstalk in vitro remain highly controversial. When challenged with carcinogens, zebrafish developed liver cancer that resembles the human liver cancer both molecularly and histopathologically. Capitalizing on the growing importance and relevance of zebrafish (Danio rerio) as an alternate cancer model, we have generated liver-specific, Tet-on-inducible transgenic lines expressing oncogenic Kras G12V , RhoA, constitutively active RhoA G14V or dominant-negative RhoA T19N . Double-transgenic lines expressing Kras G12V with one of the three RhoA genes were also generated. Based on quantitative bioimaging and molecular markers for genetic and signaling aberrations, we showed that the induced expression of oncogenic Kras during early development led to liver enlargement and hepatocyte proliferation, associated with elevated Erk phosphorylation, activation of Akt2 and modulation of its two downstream targets, p21Cip and S6 kinase. Such an increase in liver size and Akt2 expression was augmented by dominant-negative RhoA T19N , but was abrogated by the constitutive-active RhoA G14V . Consequently, induced expression of the oncogenic Kras in adult transgenic fish led to the development of hepatocellular carcinomas. Survival studies further revealed that the co-expression of dominant-negative RhoA T19N with oncogenic Kras increased the mortality rate compared with the other single or double-transgenic lines. This study provides evidence of the previously unappreciated signaling crosstalk between Kras and RhoA in regulating liver overgrowth and liver tumorigenesis. Our results also implicate that activating Rho could be beneficial to suppress the Kras-induced liver malignancies.
INTRODUCTION
Aberrant RAS signaling were found in up to 30% of all human cancers. 1 In particular, activating mutation such as G12V diminishes the ability of the RAS small GTPase to hydrolyze the bound GTP to GDP, thus rendering it constitutively active. Of the three RAS isoforms, KRAS is most frequently mutated in human cancers. 2 For example, organs forming the digestive system are strongly associated with KRAS mutation, with the pancreas being highly targeted. 3 Approximately 5% of human liver cancers were also found to harbor activating mutation of the KRAS gene. 4 Hepatocellular carcinoma (HCC), which accounted for 70-85% of deaths linked to liver cancer, 5 was ranked third in the causes of cancer mortality. 6 HCC is highly associated with hepatitis B or C viral infection, aflatoxin ingestion, alcoholism and cirrhosisinducing conditions. 7 At the molecular level, several altered/ aberrant signaling pathways that engage RAS or its effectors have been implicated in the development and progression of HCC, 8, 9 suggesting the importance of RAS in liver transformation. The Raf/ MAPK and PI3K/Akt cascades are two such downstream effectors of RAS signaling that were largely implicated in many RAS-driven tumorigenesis. 1, 4 Until recently, only one such animal model of RAS-driven HCC has been reported: transgenic mice expressing HRAS
G12V
, together with the loss of b-catenin signaling, in the liver developed HCC. 10 However, there is still a lack of appropriate animal models for studying RAS-driven HCC that would permit more systematic analyses on their impact under different genetic perturbations and signaling crosstalk, especially by Rho.
RhoA, a member of the RHO small GTPase family, is highly homologous to the RAS. They are also key molecular switches that regulate cell dynamics, cell growth and tissue development. However, unlike activating mutations of RAS, the expression levels and overall activity of RhoA were found to be elevated in many human tumors, including liver cancer. 11 Indeed, RhoA has been suggested to be a suitable prognostic marker for HCC. [12] [13] [14] These observations suggested the importance of RhoA in the formation and progression of liver malignancies.
Although much has been learnt about their individual functions and crosstalk in vitro, the physiological/pathophysiological consequences of their signaling crosstalk in vivo remain largely unknown. In addition, the roles of RhoA in RAS-mediated transformation and their crosstalk in vitro remain controversial. Many pioneering in vitro studies reported an elevated level of RhoA and/or RhoA activities in oncogenic RAS-transformed cells or a requirement of RhoA signaling for RAS-mediated transformation. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Conversely, there were also studies that reported the downregulation or noninvolvement of RhoA or RhoA effectors in oncogenic RAS-transformed cells [27] [28] [29] [30] [31] [32] [33] (see Supplementary Table  S1 for a summary of these studies). As such, the underlying molecular mechanism of signaling crosstalk between RhoA and RAS is still not well defined. Adding to the complexity, it appears that certain crosstalks are cell-type-specific, vary with the RAS subtype and depend on the kinetics and duration of RAS activation. 16 Zebrafish, D. rerio, is fast becoming a popular animal model for studying human cancers. [34] [35] [36] [37] This is primarily attributed to its low cost of zebrafish husbandry, rapid development, high fecundity, amenability to reverse and forward genetics, low incidence of spontaneous tumors, ease of application of small chemical molecules and small size of all life stages. Most importantly, carcinogen-treated zebrafish developed liver tumors that resemble human liver cancers both molecularly and histologically. 37, 38 Our laboratories have recently established the zebrafish as a model for studying small GTPase signaling [39] [40] [41] [42] and have also generated Kras transgenic lines under the constitutive expression and mifepristone-inducible system to induce HCC, respectively. 43, 44 These make zebrafish a suitable model for a more systematic study of liver development and HCC driven by the oncogenic small GTPases.
Here we report the generation of the first tetracycline-inducible (Tet-on) zebrafish HCC model driven by oncogenic Kras signaling. This system eliminates the need for the crossing of the driver and effector lines, and the zebrafish has higher tolerance for doxycycline than mifepristone as the inducer. Furthermore, transcriptomic analysis carried out on the mouse liver suggested that the Tet-on system was safer than the mifepristone-inducible system because of its smaller effect on the transcriptome. 45 We showed that induced expression of the Kras G12V caused liver enlargement, concomitant with increased Raf/MAPK and PI3K/Akt activation. The Kras G12V expression in adult transgenic also led to the development of HCC associated with increased Raf/MAPK signaling. In the double-transgenic lines, the Kras G12V -mediated liver overgrowth was augmented significantly by the dominantnegative mutant of RhoA T19N , but was significantly reduced by the constitutively active RhoA G14V . This result could, in part, be attributed to the regulation of Akt2 expression and activation in the respective double-transgenic lines. Survival studies further revealed that co-expression of RhoA T19N with oncogenic Kras increased the mortality rate significantly as compared with other single or double-transgenic lines.
RESULTS
Characterization of an inducible, liver-specific transgenic Kras G12V line of zebrafish To validate the Tet-on-inducible and liver-specific expression of the Kras G12V , doxycycline induction was performed. Liver-specific enhanced green fluorescent protein (EGFP) signal was observed in the transgenic larva (Figure 1a) , arising from the induced EGFPKras G12V expression (Figure 1b) while Ras-activation assay confirmed that the ectopically expressed EGFP-Kras G12V retained its active-form ( Figure 1c) . KRAS, like HRAS and NRAS, had to be plasma membrane-bound for effective signaling to take place especially during growth and transformation-related processes. 46 Figure 1d illustrated that EGFP-Kras G12V was enriched at the hepatocytes' plasma membrane. All these results therefore confirm that the Kras transgene expression is liver-specific and faithfully recapitulates its activity in vivo. The TO(Kras G12V ) was further examined for their impacts on liver development and cancer.
Kras G12V induces liver overgrowth by increasing hepatocyte proliferation To study the impacts of Kras G12V on liver growth, volumetric analysis of the liver in TO(Kras G12V ) larvae were performed. It was shown that the liver of the TO(Kras G12V ) larvae were significantly ). (a) Image demonstrated liver-specific expression of EGFP-Kras G12V in the transgenic six dpf larvae after doxycycline exposure. (b) Western blots of whole-embryo lysate of EGFP-positive and EGFP-negative five dpf larvae. Both panels showed a band corresponding to approximately 50 KDa in the EGFP-positive larval lysate when probed with anti-KRAS and anti-EGFP antibody. No corresponding band was observed in the EGFP-negative larvae lysate (wild-type sibling control). (c) Active RAS-RBD pull-down assay followed by western blot analysis indicated that the ectopically expressed EGFP-Kras G12V protein (B50 KDa) was GTP-bound and active. Blots were first probed with anti-EGFP antibody and developed; stripped and re-probed with anti-KRAS antibody for the second development of blots. (d) Cross-section of EGFP-positive transgenic six dpf larva imaged by confocal microscopy. The ectopically expressed EGFP-Kras G12V proteins were predominantly distributed to the plasma membrane. Section was counterstained with 4' ,6-diamidino-2-phenylindole (DAPI) to illustrate the nucleus. Scale bar: 500 mm (a) and 50 mm (d).
larger than that of the control by twofold (Figure 2a) . The Lipan line, 47 which expresses discosoma sp. red fluorescent protein (dsRED) in the liver specifically, was used as the control because of the need for fluorescence labeling. To minimize the genetic and environmental background variations, TO(Kras
G12V
) was crossed to the Lipan. The double-transgenic and Lipan were used to represent the TO(Kras G12V ) and wild-type population, respectively. To determine whether the liver overgrowth was due to any increase in proliferation, immunostaining for phosphohistone 3 (pH3), a mitosis marker, was performed. The hepatocyte proliferation rate was significantly higher in the TO(Kras G12V ) than those in the controls (Figure 2b) , indicating that the expression of Kras G12V resulted in increased hepatocyte proliferation.
Ectopically expressed Kras G12V activates the RAF/MEK/ERK and PI3K/AKT pathways Next, we examined whether the liver overgrowth and increased proliferation were associated with the activation of RAF/MEK/ERK and/or PI3K/AKT. Figures 3a and b demonstrated that the activities of the RAF/MEK/ERK and PI3K/AKT pathways were indeed increased in the TO(Kras G12V ) compared with their wild-type siblings, as shown by the increased levels of phospho-Erk and phospho-Akt2, respectively. The protein level of Akt2 was also increased in TO(Kras G12V ) compared with the wild-type control. Moreover, elevated level of phospho-p21Cip and phospho-S6 ribosomal protein (both are substrates of activate Akt) was observed in the transgenic larvae compared with the wild-type (Figures 3c and d) . Altogether, the ectopically expressed Kras G12V led to an increase in RAF/MEK/ERK and PI3K/AKT signaling, which could lead to increased hepatocyte proliferation and liver enlargement.
Kras

G12V induces HCC in vivo
Because induced Kras G12V expression caused liver enlargement in the transgenic larvae, we examined whether it could result in liver malignancies in the adult TO(Kras Figure S3) . PI3K/Akt signaling is important for liver growth and regeneration, 48, 49 and potentially a key therapeutic target and biomarker of liver malignancy. [50] [51] [52] As described earlier, the liver-specific expression of Kras G12V caused liver overgrowth in the TO(Kras G12V ) larvae, accompanied by elevated overall activity of Akt2 and phosphorylation of its downstream targets, p21Cip and S6 ribosomal protein (Figures 3c and d ). In contrast, there was no significant correlation between the perturbation of Mek/Erk signaling with the observed hepatomegaly in larvae Figure S4) . We therefore went on to further investigate the impacts of this functional crosstalk between Kras and RhoA on the regulation of Akt signaling. Figure 6a shows that co-expression of RhoA T19N with Kras G12V augmented Kras G12V -mediated liver overgrowth significantly. And this apparent synergism in the TO(Kras G12V /RhoA T19N ), when compared with the TO(Kras G12V ), was accompanied by a further increase in the expression (panel 3, Figure 6d ) and the overall activity of Akt2 (top panel, Figure 6d ; lower exposure shown as second panel). However, expression of RhoA T19N alone did not affect the liver size (Supplementary Figure S5A) , the steady state levels of Akt2 expression and its activity (Figure 6d ). These observations are unlikely due to the result of the downregulation of RhoA-Rock signaling by RhoA T19N because the inhibition of Rock with Y27632 did not phenocopy the Kras G12V /RhoA T19N -induced hepatomegaly (Supplementary Figure S5B) .
In contrast, when compared with the TO(Kras G12V ), co-expression of RhoA G14V reduced the Kras G12V -mediated liver enlargement significantly (Figure 6b ), whereas no significant changes in the liver size (Figure 6c ) or the expression level/activity of Akt2 ( Figure 6f) were observed when the wild-type RhoA was co-expressed in the TO(Kras G12V /RhoA) larvae. Strikingly, such an antagonistic effect of RhoA G14V on Kras G12V was associated with a reduction of both the expression level (panel 2, Figure 6e) , and the activities of Akt2 (top panel, Figure 6e ) and reduced phosphorylation of its substrate S6 (panel 4, Figure 6e ). Furthermore, all the changes in liver size in these double-transgenic lines were correlated with the changes in hepatocyte proliferation (Supplementary Figure S5C) . Similar to TO(RhoA T19N ), expression of RhoA G14V alone did not cause any significant change to the liver size as compared with the control (Supplementary Figure S5A) . Taken together, all these results provide the first in vivo evidence that changes in Rho signaling could antagonize or potentiate the impacts of active Ras-Akt2 signaling in controlling liver growth, thus offering suitable models to further elucidate their impacts on liver tumorigenesis.
Impacts of RhoA signaling on Kras G12V -mediated liver tumorigenesis Next, we investigated the effects of RhoA signaling on Kras G12V -mediated liver tumorigenesis. From the survival curves in Figure 7a , we observed the following: (1) 100% of the wild-type control and single RhoA transgenic fish survived the induction treatment, (2) induction of Kras G12V expression in the liver caused a significant decrease in survival compared with the wild-type, (3) co-expression of RhoA or RhoA G14V with Kras G12V did not cause any significant changes to the survival rate compared with TO(Kras G12V ) and (4) co-expression of RhoA T19N with Kras G12V led to a significant increase in death rate compared with the TO(Kras G12V ), TO(Kras G12V /RhoA) and TO(Kras To verify the major causes of death from the treatment, postmortem sampling of 'dead' fish for histopathological diagnoses were performed, and all were diagnosed with liver lesions that were characteristic of liver tumors, with the most serious form being HCC (Figures 7b-i ). There were no significant differences in the severity of the liver lesions between the three doubletransgenic lines compared with the TO(Kras G12V ), as determined by Fisher's exact test (Supplementary Table S2 ). Also no fish in any treatment group had HCC at more advance stage than grade 2. All of the TO(Kras G12V /RhoA T19N ) transgenic fish were diagnosed with HCC. Apparently, they also demonstrated higher proliferation activity (Figure 7k ) than those in the other three genotypes analyzed (Figures 7j, l and m) . The induction of RhoA, RhoA G14V or RhoA T19N expression alone did not result in any death (Figure 7a) , liver enlargement or formation of malignant liver lesion (Supplementary Figure S6) .
DISCUSSION
Kras
G12V induces liver overgrowth by activation of Ras/Erk and PI3K/Akt2/p21Cip RAS GTPases are key regulators of cell growth, survival and differentiation. Our present study shows that the liver-specific expression of the Kras G12V increases hepatocyte proliferation leading to liver overgrowth, in a process accompanied by increased Raf/MAPK and PI3K/Akt2 signaling. Increased Raf/MAPK and PI3K/AKT signaling are frequently found in many human cancers. 2, 53 In addition, we also observed an increase in Akt2 expression in the TO(Kras G12V ) compared with the control. Akt2 expression level is consistently upregulated in many human cancers and correlated with higher pathological grade tumors, for example, HCC, colon cancers, squamous cell carcinomas and gliomas. [54] [55] [56] [57] Furthermore, p21Cip is found to be inactivated by heightened Akt2-mediated inhibitory phosphorylation of the p21Cip protein. Phosphorylation of p21Cip at threonine 145 is a negative regulator of its function and disrupts the inhibitory interaction with proliferating cell nuclear antigen, [58] [59] [60] thus promoting proliferation and cell survival. Such phosphorylation by AKT also causes the protein to reside in the cytosol, thus preventing its inhibitory interaction with the cyclin-dependent kinase or proliferating cell nuclear antigen. 61 Taken together, the TO(Kras G12V ) offers a suitable model for studying oncogenic Kras signaling as it faithfully recapitulates the major signaling pathways perturbed by activating mutation of RAS. Indeed, we have provided evidence here that the active RhoA could suppress the induction of Akt expression by Kras
G12V
, and thus suppresses liver enlargement and proliferation of hepatocytes, whereas its dominant-negative form augments the effects of Kras in all those processes, leading to greater mortality rates (see later part of Discussion).
Kras
G12V promotes development of HCC in adult zebrafish Activating mutation of Kras has a central role in the progression of many human cancers. Here we show that induced expression of Kras G12V in the liver led to the formation of HCC, with increased proliferation and Ras/Erk activities. The phospho-Erk1/2 was largely localized to the nucleus, consistent with the view that the activated Erk1/2 needs to translocate to the nucleus for activating the transcription factors for mitogenic responses. 62 Impaired nucleus translocation of activated Erk1/2 (cytosolic retention) not only reduced cell proliferation and survival signals but also activated death-associated protein kinase to promote apoptosis. 62 Interestingly, we have reported a spatial regulation of Erk1/2 activation that could be attributed to the interplay of physical and biological signals. Similar spatial regulation of ERK phosphorylation/activation is reported recently in an in vitro study using epithelial cells as the model. 63 These findings further illustrate the relevance of the TO(Kras Immunohistochemical staining of the paraffin section with proliferation marker, proliferating cell nuclear antigen (PCNA) (brown); g showed a significant increase in the staining as compared with h and i. (j, k) Increased phospho-Erk1/2 staining was observed in the TO(Kras G12V ) compared with the wild-type control. The staining of the phosho-Erk1/2 was mainly observed in the nucleus. Scale bar for a-c is 1 cm. Scale bar for d-k is 50 mm. transformation or RAS-driven transformation necessitates RhoA signaling input. Our findings provide the evidence for the functional crosstalk of RAS and Rho in an in vivo animal model. We showed that the expression of the dominant-negative RhoA T19N augments Kras G12V -mediated liver overgrowth, HCC development and cancer mortality. And in strong contrast, the expression of constitutively active RhoA G14V helped suppress Kras G12V -driven liver overgrowth in the larvae at least through a reduction in Akt2 expression and activation with a concomitant reduction in hepatocyte proliferation. These results suggest that active RhoA has an important inhibitory role in Kras oncogenic signaling. Consistent with our in vivo data, constitutive-active RhoA has been shown to inhibit AKT activation. 64, 65 Supportive of the notion that increased RhoA activities could disrupt AKT activation, RhoA T19N has been demonstrated to promote the activation of AKT. 65, 66 Moreover, activation of RhoA by vasopressin can downregulate cyclin D1 expression, leading to the inhibition of oncogenic Kras-driven proliferation. 67 In another study, it was demonstrated that RhoA G14V could inhibit proliferation by slowing down G1-to S-phase cell cycle transition and hindering the completion of cytokinesis. 68 It is worth noting that many studies that demonstrate the requirement of active RhoA in RAS transformation utilize the HRAS isoform instead of the KRAS isoform (Supplementary Table S1 ). Furthermore, all studies, except the study by Vidal et al. 25 , use a fibroblast cell type instead of epithelial cell type to which the hepatocytes belong. [15] [16] [17] [18] [19] [21] [22] [23] [24] [25] The fibroblast cell type responds differently from the epithelial cell type when activated RAS is introduced. Thus, the fibroblast may be an inappropriate model for RAS-induced transformation. 69 Other reports support our finding that RhoA signaling does not augment or support Ras transformation. 28, [30] [31] [32] Interestingly, two out of these studies that supported our findings employed the KRAS mutants in their experimental setup, and one of these two studies utilized an epithelial cell type for their investigation. 28, 31 It was suggested that this crosstalk of RAS and Rho depends on cell types, RAS isoforms and duration of RAS activation. 16 In summary, we provided evidence of a previously underappreciated, signaling crosstalk between Kras and RhoA in regulating liver overgrowth, hepatocyte transformation and cancer mortality. Specifically, such an inducible transgenic system offers an exciting platform for modeling human HCC, and as an alternative in vivo model for studying the physiological roles of small GTPase signaling and their possible interplay in regulating normal organ development and disease manifestation. In this context, we showed that halting RhoA signaling could augment Kras-mediated liver overgrowth and tumorigenesis. These data could have far reaching influence on the development and application of therapeutics directed at inhibiting RhoA signaling in KRAS-driven tumors. Furthermore, our results implicate that activating Rho could be beneficial to suppress Kras-induced liver malignancies.
MATERIALS AND METHODS
Zebrafish maintenance
Zebrafish were maintained in compliance with the Institutional Animal Care and Use Committee guidelines of National University of Singapore.
Generation of the Tg(fabp10:rtTA2s-M2;TRE2:EGFP-kras G12V ) zebrafish Transgenic founders were created by the co-injection of linearized pfabp10-rtTA2s-M2 (fabp10 promoter 70 upstream of rtTA2s-Ms) 71 and pTRE2-eGFP-Kras G12V into one-cell stage embryo. Zebrafish kras gene was described in Liu et al. 41 and site-directed mutagenesis performed on pGEM-T kras with primer pair 5 0 -GTGGTCGTGGGAGCTGTCGGCGTAGGC AAAAGC-3 0 and 5 0 -GCTTTTGCCTACGCCGACAGCTCCCACGACCAC-3 0 to obtain pGEM-T Kras G12V (Site-Directed Mutagenesis Kit, Agilent, La Jolla, CA, USA). The kras G12V was subcloned into pTRE2-EGFP vector. Injected embryos were raised to adulthood. Potential F0 fish were screened by outcrossing to wild-type stock. One F0 fish was identified and used to establish the stable transgenic line Tg(fabp10:rtTA2s-M2;TRE2:EGFPkras G12V ), named TO(kras G12V Figure S7A) .
) in this communication (Supplementary
Generation of the Tg(fabp10:rtTA2s-M2:TRE2:mCherry-rhoA) zebrafish mCherry and rhoA genes were subcloned into pTRE2 vector (Clontech, Mountain View, CA, USA) from the pmCherry (Clontech) and pCS2 þ rhoA* vector, 40 respectively. The rhoA* represents the wild-type rhoA, constitutive-active rhoA G14V or the dominant-negative rhoA T19N in this communication for ease of presentation. Subsequently, the fabp10-rtTA2s-M2 and TRE2-mCherry-rhoA* were subcloned into the pDS vector 72 to yield pDS-fabp10-rtTA2s-M2-TRE2-mCherry-rhoA* vector. Transgenic rhoA zebrafish were generated using the Ac/Ds transposon system as described previously 72 by co-injection of plasmid with Ac mRNA into one-cell stage embryo. Microinjected embryos were raised to adulthood and screened for founders. One founder was selected from each rhoA group to establish the stable line for each line (Supplementary Figure S7B) .
The RhoA stable transgenic lines were named TO(RhoA*) in this communication. Progenies derived from the crossing between the TO(kras G12V ) and TO(RhoA*) were subsequently named TO(Kras G12V /RhoA*).
Induction of transgene expression with doxycycline
Two dpf larvae were treated with doxycycline (20 mg/ml) (Sigma-Aldrich, St Louis, MO, USA) and screened for fluorescence (EGFP or mCherry) at five dpf by fluorescence microscopy. Larvae were sorted according to the expression of difference fluorescence (EGFP and/or mCherry). They were documented with Zeiss AxioVert microscope (Carl Zeiss, Oberkochen, Germany). For the induction study, approximately 3-month-old fish were used. Eight different genotypes, each divided in two groups (treated vs control; 40 fish each), were studied. They were housed in tank with five fish to 1 l of water aerated with an air pump. Tanks were housed in the dark throughout the treatment. Water was changed every other day, and dosed with doxycycline (10 mg/ml) for the treatment group and none for the control. Death events were defined as follows: (1) dead and rotten, (2) freshly dead and (3) near-dead fish. The near-dead fish were Killed. Survival analysis by log-rank test was performed with GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). Differences were considered significant at Pvalue o0.01. Dead/Killed fish were sampled for histopathological diagnoses. The tumor incidences were analyzed statistically at P-value o0.05 by Fisher's exact test. Confocal microscopy-volumetric analysis of the larvae liver Six dpf larvae were fixed overnight in 4% paraformaldehyde (Sigma-Aldrich) at 4 1C. Fixed larvae were washed with phosphate-buffered saline (PBS) with 0.1% Tween 20 and cleared in a progressive increment of glycerol from 10 to 50% in PBS. They were stored overnight in 50% glycerol/PBS/2.5% 1,4-diazabicyclo[2. Immunohistochemical staining was performed with anti-proliferating cell nuclear antigen (anti-PCNA) to demonstrate the accompanied increased hepatocyte proliferation in the HCC samples. Slides were counterstained with hematoxylin. The TO(Kras G12V /RhoA T19N ) transgenic fish demonstrated an apparently higher proliferation rate than the other three transgenic lines. Scale bar: 1 cm (b-e), 50 mm (f-i) and 100 mm (j-m).
created, and volumes occupied by the fluorescence signals were estimated by the surface creation wizard. T-tests were performed to determine differences statistically at P-value o0.01.
Immunostaining of cryostat section
Cross-sections of 10 mm were cut using a cryostat microtome (Lecia) following the protocol described in Zhu et al. 39 and Westerfield. 73 Slides were washed in PBS and were either stained with 4',6-diamidino-2-phenylindole (Life Technologies, Carlsbad, CA, USA) and mounted for direct viewing or used for immunostaining. For immunofluorescence, the sections were blocked and permeabilized with blocking solution (5% goat serum/PBS/0.3% Triton X-100). Anti phospho-histone 3 antibody (1:200) (Millipore, Billerica, MA, USA) in blocking solution was applied and incubated at 4 1C overnight. The slides were washed thrice in PBS. Alexafluor647 antibody (1:200) (Life Technologies) were applied and incubated for 2 h at room temperature. Slides were washed thrice in PBS, counterstained with 4',6-diamidino-2-phenylindole and mounted with fluorsave (Calbiochem, San Diego, CA, USA). Images were captured with Zeiss LSM510 Meta microscopy (Carl Zeiss) or Lecia MP Â 5 and analyzed with ImageJ (National Institutes of Health, Bethesda, MD, USA). Differences were considered significant at P-value o0.05 by t-test.
Histological preparation and analyses
Live adult fish were anaesthetized in 0.5% phenoxyethanol (SigmaAldrich), Killed and fixed in Bouin's fixative (saturated picric acid: 37% formalin: acetic acid, 15:5:1) (Sigma-Aldrich) for 4 days at room temperature. Dead fish were fixed directly. The fixed specimens were embedded in paraffin (Sigma-Aldrich). Sectioning of paraffin blocks into 5-mm sections (sagittal) and hematoxylin and eosin staining were prepared by Biopolis Shared Facilities (IMCB, Singapore). Histopathological diagnoses on the hematoxylin and eosin slides were performed to determine the presence of liver lesion based on criteria described previously, 38, 71, 74, 75 which includes the loss of the two-cell sheet organization, pleomorphism and vesicular nuclei with one or multiple nucleoli.
Immunostaining of paraffin section
Sections were deparaffined, rehydrated and heat-processed in antigen retrieval solution (10 mM sodium citrate buffer, pH 6.0, 0.5% Tween 20) . Processed slides were used either for immunohistochemical or immunofluorescence staining.
Immunohistochemical was performed with EnVision þ HRP system (Dako, Glostrup, Denmark). Sections were treated with Dako peroxidase block for 15 min, and followed by 1 h of incubation with blocking buffer (10% goat serum/Tris-buffered saline (TBS)/1% bovine serum albumin). Anti-proliferating cell nuclear antigens (1:75) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in 1% bovine serum albumin/TBS were applied and incubated at 4 1C overnight. Slides were washed in TBS plus Tween 20 and incubated at room temperature with Dako polymer/HRP for 30 min. Slides were washed in TBS plus Tween 20, developed with Dako DAB þ staining buffer, counterstained with hematoxylin and mounted with Permount (Fisher Scientific, Rockford, IL, USA). Documentation was performed using the Zeiss Axioskop2 microscopy (Carl Zeiss). For immunofluorescence study, the peroxidase blocking step was omitted and the polymer/HRP was replaced with Alexa-fluor488 and/or Alexa-fluor546 (1:200) (Life Technologies) and incubated for 2 h. Sections were probed with anti-phosphoErk1/2 (1:1000) (Sigma-Aldrich) and/or anti-EGFP (1:100) (Life Technologies). Documentation of staining was performed using the Zeiss LSM510 Meta microscopy (Carl Zeiss).
Western blot analysis with larvae and adult liver tissue For the larvae total lysate, approximately 50 five dpf larvae were lysed in radio immunoprecipitation assay (RIPA) buffer. 39 A volume of 2.5-3.0 ml of radio immunoprecipitation assay buffer was used per larva. Total protein concentration was estimated with bicinchoninic acid protein assay (Piercenet, Rockford, IL, USA). Samples were denatured at 90 1C for 3 min in laemmli buffer. Total protein of 20 mg was resolved on 8 or 12% SDSpolyacrylamide gel and transferred to polyvinylidene difluoride membrane. Ras-activation assay was performed with larval lysate as described in Ravichandran and Low. 76 For determination of mCherry-RhoA* expression in TO(RhoA*), adult fish were subjected to doxycycline induction (60 mg/ml) for 1 week and Killed. Liver tissues were harvested and lysed in T-per (Piercenet) supplemented with cocktail proteinase inhibitor (Roche, Basel, Switzerland), with 25-30 ml used per mg of tissue. The tissues were grinded with a pellet pestle for at least 2 min and incubated in the cold with strong agitation for 2 h before centrifugation at maximum speed for 20 min at
